PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 06/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. AKTX, BDRX, AADI, LIAN, MAAQ, BRNS, ACRV, CLNN, OKUR, and ELYMShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Akari Therapeutics (AKTX), Biodexa Pharmaceuticals (BDRX), Aadi Bioscience (AADI), LianBio (LIAN), Mana Capital Acquisition (MAAQ), Barinthus Biotherapeutics (BRNS), Acrivon Therapeutics (ACRV), Clene (CLNN), OnKure Therapeutics (OKUR), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Akari Therapeutics Biodexa Pharmaceuticals Aadi Bioscience LianBio Mana Capital Acquisition Barinthus Biotherapeutics Acrivon Therapeutics Clene OnKure Therapeutics Eliem Therapeutics Akari Therapeutics (NASDAQ:AKTX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Which has more risk and volatility, AKTX or PHXM? Akari Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Does the MarketBeat Community prefer AKTX or PHXM? Akari Therapeutics received 262 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26249.53% Underperform Votes26750.47% PHAXIAM TherapeuticsN/AN/A Is AKTX or PHXM more profitable? Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A Which has higher earnings & valuation, AKTX or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/APHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media favor AKTX or PHXM? In the previous week, Akari Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for PHAXIAM Therapeutics. Akari Therapeutics' average media sentiment score of 1.87 beat PHAXIAM Therapeutics' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akari Therapeutics Very Positive PHAXIAM Therapeutics Neutral Do insiders & institutionals hold more shares of AKTX or PHXM? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAkari Therapeutics beats PHAXIAM Therapeutics on 5 of the 8 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$127.71M$5.61B$8.62BDividend YieldN/A3.74%5.28%4.17%P/E RatioN/A3.3127.1419.96Price / Sales0.324,216.94411.83157.63Price / CashN/A13.1938.2534.64Price / Book0.3936.957.064.69Net Income-$240K-$91.56M$3.23B$248.14M7 Day PerformanceN/A2.02%2.67%2.39%1 Month PerformanceN/A7.86%8.82%6.05%1 Year PerformanceN/A176.00%31.44%13.60% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AKTXAkari TherapeuticsN/A$1.31-3.0%N/A-61.0%$42.15MN/A0.009Positive NewsGap DownBDRXBiodexa Pharmaceuticals0.5211 of 5 stars$1.15-0.9%N/AN/A$42.03M$83K0.0020Short Interest ↑AADIAadi Bioscience0.6014 of 5 stars$1.69-0.6%$1.67-1.4%+15.0%$41.74M$25.07M-0.7440Gap UpLIANLianBioN/A$0.38+2.4%N/A+15.3%$40.96MN/A-0.47110MAAQMana Capital AcquisitionN/A$4.99+13.4%N/A+716.2%$40.54MN/A0.001High Trading VolumeBRNSBarinthus Biotherapeutics2.86 of 5 stars$0.99-2.0%$5.17+421.9%-46.1%$39.94M$14.97M-0.66107ACRVAcrivon Therapeutics4.2634 of 5 stars$1.25+1.6%$17.71+1,317.1%-82.8%$39.19MN/A-0.4658Positive NewsAnalyst RevisionHigh Trading VolumeCLNNClene2.5705 of 5 stars$4.33+7.7%$40.00+823.8%-49.3%$38.90M$350K-0.82100Short Interest ↑OKUROnKure Therapeutics3.6549 of 5 stars$2.86-1.0%$32.33+1,030.5%N/A$38.64MN/A-0.23N/ANews CoverageELYMEliem TherapeuticsN/A$1.29flatN/A-83.5%$38.38MN/A-2.439 Related Companies and Tools Related Companies Akari Therapeutics Competitors Biodexa Pharmaceuticals Competitors Aadi Bioscience Competitors LianBio Competitors Mana Capital Acquisition Competitors Barinthus Biotherapeutics Competitors Acrivon Therapeutics Competitors Clene Competitors OnKure Therapeutics Competitors Eliem Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHXM Stock Free PHXM Stock Alerts